2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
SUZHOU, China, April 23, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC)...
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
SUZHOU, China, April 22, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), independently...
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
SUZHOU, China, April 1, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technology Co.,...
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
SUZHOU, China, March 26, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights KN026 (Anbenitamab) achieved robust...
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
SUZHOU, China, March 24, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN026) in combination...
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
SUZHOU, China, March 20, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug...
Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer
SUZHOU, China, March 18, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced the appointment of Mr. Fei Wang as Chief Financial Officer (CFO). Mr. Wang will be responsible for the company's capital operations, investment and...
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed...
Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE
SUZHOU, China, March 13, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate...
Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer
SUZHOU, China, March 11, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the appointment of Dr. Hongwei Wang as Chief Technology Officer (CTO). Dr. Wang will be responsible for the company's Process Development and Analytical...